Benchmark analyst Bill Sutherland said he expects the healthcare services sector to remain "a relatively quiet port in the current market storm." Given his view that the sector's performance is more impacted by regulatory and reimbursement trends, he believes that BioTelemetry (BEAT) and Select Medical (SEM), which each enjoy benign reimbursement trends and almost no exposure to the "consumerism" pressures, look particularly well positioned in the current environment, he tells investors. The firm has a Buy rating and $44 price target on BioTelemetry and Buy rating with a $23 target on Select Medical.